|
Standard
Health Package:
STD Basic
Package : 250.00
Fasting Required:
No; Specimen: Blood;
Results: 3-5 Business Days
Tests
Included:
HSV II: There is
a considerable homology between
HSV I and HSV II antigens, so
that antibodies formed against
either virus are highly
cross-reactive. This assay is
based on purified recombinant
G-2 antigen and is specific for
type II antibodies. Moreover,
this assay is highly sensitive
and specific and will not detect
antibodies to HSV I.
HIV: Human
immunodeficiency virus (HIV
1/O/2), the etiologic agent of
the acquired immunodeficiency
syndrome (AIDS) is a cytopathic
retrovirus. This test uses
recombinant antigen sources and
detects antibodies by specific
immune binding and subsequent
chemiluminescent reaction (ICMA
technology). Sensitivity and
specificity of this assay are
100% and 99.9% respectively.
Sera which are repeatedly
reactive in two out of three
tests are subject to
confirmatory HIV-1 testing by
the Western blot method. Some
individuals may be initially
reactive by the preliminary test
and negative or indeterminate by
Western blot. This may be caused
by other viral antibodies or
autoantibodies which cross react
with the viral antigens although
this is rare.
Hepatitis C:
Following the development of
sensitive and specific testing
for hepatitis B, 90% of
post-transfusion hepatitis is
now hepatitis C. A gene product
(c100) of hepatitis C virus
(HCV) was isolated and an assay
for anti-HCV developed. The
assay detects antibody to a
presumptive togavirus or
flavivirus which may be an
etiologic agent of non-A, non-B
hepatitis (which may not be a
unitary disease entity).
For blood donors, hepatitis C
serology correlates with
surrogate tests for non-A, non-B
hepatitis (ALT and anti-HBc).
Since hepatitis C serology
identifies a broader group of
infected individuals than
surrogate testing, it reduces
risk of HCV during transfusion.
Studies in hemophiliacs indicate
that antibody to HCV is a
reliable marker of HCV.
STD
Comprehensive Package –495.00
Fasting Required:
No; Specimen: Blood;
Results: 3-5 Business Days
Tests
Included:
Chlamydia/Gonorrhea:
Clamydia trachomatis and
Neisseria gonorrhoeae are the
most common sexually-transmitted
diseases. In 2002, the Centers
for Disease Control and
Prevention published guidlines
for laboratory testing that
emphasized the use of nucleic
acid amplification tests for
screening for Chlamydia
trachomatis and also for
Neisseria gonorrhoeae when
conditions of transport could
compromise viability of the
organism.1,2 Other guidelines
have recommended Chlamydia
screening for all women 15-25,
as well as testing pregnant
women during their first
trimester for both Chlamydia and
Neisseria. In some settings, the
fact that both Neisseria and
Chlamydia testing can be
performed on the same specimen
testing for both can be an
effective strategy.
RPR
Qualitative: The
test is looking for evidence of
Treponema pallidum, the
bacterium that causes syphilis.
Syphilis is a common sexually
transmitted disease. It is
easily treated but can cause
severe health problems if left
untreated.
HIV
1: Human
immunodeficiency virus (HIV
1/O/2), the etiologic agent of
the acquired immunodeficiency
syndrome (AIDS) is a cytopathic
retrovirus. This test uses
recombinant antigen sources and
detects antibodies by specific
immune binding and subsequent
chemiluminescent reaction (ICMA
technology). Sensitivity and
specificity of this assay are
100% and 99.9% respectively.
Sera which are repeatedly
reactive in two out of three
tests are subject to
confirmatory HIV-1 testing by
the Western blot method. Some
individuals may be initially
reactive by the preliminary test
and negative or indeterminate by
Western blot. This may be caused
by other viral antibodies or
autoantibodies which cross react
with the viral antigens although
this is rare.
HSV
I&II: Detect
herpes simplex I and II DNA in
clinical specimens; when
performed on cerebrospinal
fluid, supports a diagnosis of
herpes simplex encephalitis and
herpes simplex meningitis
Hepatitis A Antibody IgM:
Hepatitis A virus is a
picornavirus, and antibody is
made to capsid proteins. Fecal
excretion of HAV peaks before
symptoms develop. If hepatitis A
antibody is IgM, the hepatitis A
infection is probably acute. IgM
antibody develops within a week
of symptom onset, peaks in 3
months, and is usually gone
after 6 months. Hepatitis A
antibody of IgG type is
indicative of old infection, is
found in almost 50% of adults
and is not usually clinically
relevant. Many cases of
hepatitis A are subclinical,
particularly in children.
Presence of IgG antibody to HAV
does not exclude acute hepatitis
B or other forms of hepatitis.
Hepatitis B Core Antibody IgM:
Differential diagnosis of
hepatitis; also used in
conjunction with other B viral
serologic markers, to assess the
stage of hepatitis B infection.
At times this may be the only
demonstrable marker for the
diagnosis of current or past
hepatitis B viral infection.
Hepatitis B Surface Antibody:
Used to evaluate possible
immunity in individuals who are
at increased risk for exposure
to hepatitis B.
Hepatitis B Surface Antigen:
Hepatitis B virus (HBV) is a DNA
virus with a protein coat, the
surface antigen (HBsAg) and a
nucleic acid core, the core
antigen (HBcAg). There are eight
different serotypes. Early in
infection, HBsAg, HBV DNA, and
DNA polymerase can all be
detected in serum.
HBsAg can be detected 1-7 weeks
before liver enzyme elevation or
the appearance of clinical
symptoms. Three weeks after the
onset of acute hepatitis, about
50% of patients will still be
positive for HBsAg, while at 17
weeks only 10% are positive. The
best available markers for
infectivity are HBsAg and HBeAg.
The presence of anti-HBs is
frequently associated with
noninfectivity. The chronic
carrier state is indicated by
the persistence of HBsAg and/or
HBeAg over long periods (6
months to years) without
seroconversion to the
corresponding antibodies. Such a
condition has the potential to
lead to serious liver damage,
but may be an isolated
asymptomatic serologic
phenomenon.
Persistence of HBsAg, without
anti-HBs, with combinations of
positivity of anti-HBc, HBeAg,
or anti-HBe indicates
infectivity and need for
investigation for chronic
persistent or chronic aggressive
hepatitis.
Hepatitis C Antibody:
Following the development of
sensitive and specific testing
for hepatitis B, 90% of
post-transfusion hepatitis is
now hepatitis C. A gene product
(c100) of hepatitis C virus
(HCV) was isolated and an assay
for anti-HCV developed. The
assay detects antibody to a
presumptive togavirus or
flavivirus which may be an
etiologic agent of non-A, non-B
hepatitis (which may not be a
unitary disease entity).
For blood donors, hepatitis C
serology correlates with
surrogate tests for non-A, non-B
hepatitis (ALT and anti-HBc).
Since hepatitis C serology
identifies a broader group of
infected individuals than
surrogate testing, it reduces
risk of HCV during transfusion.
Studies in hemophiliacs indicate
that antibody to HCV is a
reliable marker of HCV.
_______________________________________________________________
Individual
Tests without Package:
Vaginosis
Profile(Women)-180.00
This
test evaluates vaginal bacteria,
yeast, cytolysis, leukocytes,
RBCs and Trichomonas
_____________________________
Herpes
Simplex Virus I & II, IgG
-218.00
Fasting Required:
No; Specimen: Blood;
Results: 5-7 Business Days
Description: Conventional
HSV-1 and HSV-2 assays cannot
differentiate HSV type 1 from
HSV type 2 infection due to the
extensive homology of viral
antigens. Antibodies formed
against either virus are highly
cross reactive. An HSV-2
type-specific IgG assay based on
glycoprotein G-2 is available
for differentiating HSV-1 from
HSV-2 infections.
Herpes
Simplex Virus, II-129.00
Fasting Required:
No; Specimen: Blood;
Results: 5-7 Business Days
__________________________________________
Chlamydia/Gonorrhea -235.00
Fasting Required:
No; Specimen: Urine;
Results: 5-6 business days
__________________________________________
HIV, DNA by
PCR w/ HIV Abs by ICMA -180.00
Fasting Required:
No; Specimen: Blood;
Results: 5-7 Business Days
Description:
The HIV-1 DNA by PCR test looks
directly for the proviral DNA as
well as the antibodies for HIV-1
and HIV-II. The complex HIV-1
PCR test is 99% accurate at 28
days or more from a suspected
contact or exposure.
HIV-I
-115.00
Fasting Required:
No; Specimen: Blood;
Results: 5-7 Business Days
Description:
Antibody testing will not
detect HIV immediately after
exposure, during the window
before the development of
antibodies. If you are tested
too soon, your result may be
negative.
HIV-I Ab,
Western Blot -230.00
Fasting Required:
No; Specimen: Blood;
Results: 5-7 Business Days
Description: In the
Western blot procedure,
electrophoretically separated
HIV proteins and glycoproteins
are overlaid with serum.
Antibodies present will bind to
the appropriate antigen, which
is spatially separated by
molecular weight from other
viral components. The bound
antibody is then visualized by
reaction with a labeled antibody
to human immunoglobulin or
protein A.
________________________________________________-
RPR,
Qualitative (Syphillis)-80.00
Fasting Required:
No; Specimen: Blood;
Results: 3-5 Business Days
Description: The test is
looking for evidence of
Treponema pallidum, the
bacterium that causes syphilis.
Syphilis is a common sexually
transmitted disease. It is
easily treated but can cause
severe health problems if left
untreated.
________________________________________________-
Hepatitis
Package-259.00
Fasting Required:
No; Specimen: Blood;
Results: 5-7 Business Days
Hepatitis is a liver disease.
There are two kinds of hepatitis
– those caused by viruses and
those caused by chemicals or
drugs.
Tests
Included:
Hepatitis A Antibody, IgM:
Hepatitis A virus is a
picornavirus, and antibody is
made to capsid proteins. Fecal
excretion of HAV peaks before
symptoms develop. If hepatitis A
antibody is IgM, the hepatitis A
infection is probably acute. IgM
antibody develops within a week
of symptom onset, peaks in 3
months, and is usually gone
after 6 months. Hepatitis A
antibody of IgG type is
indicative of old infection, is
found in almost 50% of adults
and is not usually clinically
relevant. Many cases of
hepatitis A are subclinical,
particularly in children.
Presence of IgG antibody to HAV
does not exclude acute hepatitis
B or other forms of hepatitis.
Hepatitis B Core Antibody:
Differential diagnosis of
hepatitis; also used in
conjunction with other B viral
serologic markers, to assess the
stage of hepatitis B infection.
At times this may be the only
demonstrable marker for the
diagnosis of current or past
hepatitis B viral infection.
Hepatitis B Surface Antigen:
Hepatitis B virus (HBV) is a DNA
virus with a protein coat, the
surface antigen (HBsAg) and a
nucleic acid core, the core
antigen (HBcAg). There are eight
different serotypes. Early in
infection, HBsAg, HBV DNA, and
DNA polymerase can all be
detected in serum.
HBsAg can be detected 1-7 weeks
before liver enzyme elevation or
the appearance of clinical
symptoms. Three weeks after the
onset of acute hepatitis, about
50% of patients will still be
positive for HBsAg, while at 17
weeks only 10% are positive. The
best available markers for
infectivity are HBsAg and HBeAg.
The presence of anti-HBs is
frequently associated with
noninfectivity. The chronic
carrier state is indicated by
the persistence of HBsAg and/or
HBeAg over long periods (6
months to years) without
seroconversion to the
corresponding antibodies. Such a
condition has the potential to
lead to serious liver damage,
but may be an isolated
asymptomatic serologic
phenomenon.
Persistence of HBsAg, without
anti-HBs, with combinations of
positivity of anti-HBc, HBeAg,
or anti-HBe indicates
infectivity and need for
investigation for chronic
persistent or chronic aggressive
hepatitis.
Hepatitis C Antibody:
Following the development of
sensitive and specific testing
for hepatitis B, 90% of
post-transfusion hepatitis is
now hepatitis C. A gene product
(c100) of hepatitis C virus
(HCV) was isolated and an assay
for anti-HCV developed. The
assay detects antibody to a
presumptive togavirus or
flavivirus which may be an
etiologic agent of non-A, non-B
hepatitis (which may not be a
unitary disease entity).
For blood donors, hepatitis C
serology correlates with
surrogate tests for non-A, non-B
hepatitis (ALT and anti-HBc).
Since hepatitis C serology
identifies a broader group of
infected individuals than
surrogate testing, it reduces
risk of HCV during transfusion.
Studies in hemophiliacs indicate
that antibody to HCV is a
reliable marker of HCV.
|
